Evelo dealt another blow with a PhII fail, plans for strategic alternatives

Anna Brown

News Reporter

Evelo Biosciences is exploring strategic alternatives for its mid-stage psoriasis treatment after it reported that another psoriasis drug failed a Phase II clinical trial. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Evelo dealt another blow with a PhII fail, plans for strategic alternatives

Anna Brown

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

Arcus touts early kidney cancer data as Gilead declines option

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Evelo dealt an­oth­er blow with a PhII fail, plans for strate­gic al­ter­na­tives

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Evelo dealt another blow with a PhII fail, plans for strategic alternatives